Arrowhead Research Corp  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for Kenneth D. Lewis
3.18
-0.06 (-1.85%)
After Hours: 3.15 -0.03 (-0.94%)
Feb 9, 6:07PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.11 - 3.40
52 week 3.11 - 9.36
Open 3.27
Vol / Avg. 814,142.00/996,376.00
Mkt cap 177.56M
P/E     -
Div/yield     -
EPS -1.57
Shares 59.55M
Beta 2.15
Inst. own 44%
Mar 8, 2016
Arrowhead Research Corp Annual Shareholders Meeting - 1:00PM EST - Add to calendar
Mar 2, 2016
Arrowhead Research Corp Annual Shareholders Meeting (Estimated) - 1:00PM EST - Add to calendar
Feb 9, 2016
Q1 2016 Arrowhead Research Corp Earnings Call
Feb 9, 2016
Q1 2016 Arrowhead Research Corp Earnings Release
Dec 14, 2015
Q4 2015 Arrowhead Research Corp Earnings Call - Webcast
Dec 14, 2015
Q4 2015 Arrowhead Research Corp Earnings Release
Dec 2, 2015
Arrowhead Research Corp at Piper Jaffray Healthcare Conference
Nov 19, 2015
Arrowhead Research Corp at Jefferies Global Healthcare Conference
Nov 16, 2015
Arrowhead Research Corp Analyst and Investor Reception - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin -56555.75% -24068.29%
Operating margin -57668.18% -25124.08%
EBITD margin - -24512.51%
Return on average assets -71.54% -58.36%
Return on average equity -82.20% -66.45%
Employees 104 -
CDP Score - -

Address

Suite 1050, 225 South Lake Avenue
PASADENA, CA 91101
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company’s drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Officers and directors

Douglas B. Given M.D., Ph.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
David L. Lewis Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Peter Brian Leone Vice President-Strategy & Program Management
Age: 59
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 52
Bio & Compensation  - Reuters
Michael S. Perry Ph.D. Lead DirectorLead Independent Director
Age: 56
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D Independent Director
Age: 56
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 79
Bio & Compensation  - Reuters